Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Viruses may one day help treat brain tumors

08.04.2005


New research shows that a virus designed to kill cancer cells can significantly increase the survival of mice with an incurable human brain tumor, even in some animals with advanced disease.



The study used a genetically altered herpes simplex virus that infects and reproduces only in malignant glioma cells and kills them. The altered virus leaves normal tissues unharmed. Viruses that kill cancer cells are known as oncolytic viruses.

The findings are published in the April 1 issue of the journal Cancer Research. “This is another step toward making oncolytic viruses more effective and safer for use in the treatment of cancer,” says E. Antonio Chiocca, professor and chairman of neurological surgery at The Ohio State University Medical Center. “This is a preliminary study,” Chiocca emphasized. “This virus cannot yet be used in humans. To go from animal studies to human studies is a very long process, especially for a treatment that uses viruses.”


Malignant gliomas are cancers in the brain that progress quickly after diagnosis. They are nearly always fatal, Chiocca says. The average survival following diagnosis is about a year. They are usually treated using surgery, chemotherapy and radiation. “Unfortunately, the average survival time for these patients has not improved in more than 30 years,” says Chiocca, who also directs OSU’s Dardinger Center for Neuro-oncology and co-leads the Viral Oncogenesis Program at the OSU Comprehensive Cancer Center. “There is a real need for new therapies.”

He believes oncolytic viruses offer a promising new strategy. Chiocca’s collaborators for the study included Yoshinaga Saeki, associate professor of neurosurgery, who directed the research, and first author Hirokazu Kambara, a post-doctoral fellow.

The study began with a laboratory version of a herpes virus that was missing several genes. The virus could infect only malignant glioma cells, but once inside the cells, it reproduced, or replicated, poorly. “Instead of making 1,000 copies of itself, it might only make 10,” Chiocca says. The virus therefore had only a weak ability to kill cancer cells and shrink tumors.

For this study, Saeki, Kambara and Chiocca restored the virus’s ability to replicate at high levels by returning one of the genes that had been removed from the virus. First, though, the researchers modified the gene, known as ICP34.5, so that it would be active only in cells that made a protein called nestin.

Why nestin? Usually, cells make nestin only during embryonic development. After that, it is absent from cells. But malignant glioma (and some other cancers) begin producing nestin again. This sets the cancer cells apart from normal cells and gave the researchers the trigger they needed.

The researchers tested the modified virus first in laboratory-grown malignant glioma cells. They found that the ICP34.5 viruses could again replicate at high levels.

Then the researchers tested the virus in mice with implanted human gliomas. In one set of experiments, the researchers gave the virus to the mice early, seven days after implanting the tumors. Untreated mice lived for 21 days after tumor implantation. Eight of 10 mice treated with the ICP34.5 virus survived 90 days after implantation. Two of 10 mice treated with a control virus survived 90 days.

The control virus was very similar to a type used in clinical trials testing viral treatment of malignant glioma. It was similar to the experimental virus, but it lacked the ICP34.5 gene. But human glioma patients are usually diagnosed and treated later in the disease, after symptoms begin. The researchers therefore conducted an experiment that simulated that condition. They injected the virus into tumors 19 days after implantation and when the mice began showing symptoms, which is similar to the case in human treatment.

In this experiment, two of 10 animals treated with the ICP34.5 virus survived 24 days after implantation. Of mice treated with the control virus, all 10 had died by day 21, a statistically significant difference. “The treatment extended the animals’ lives by several days,” Chiocca says. “If we could achieve a proportional increase in humans with malignant glioma, that would be a very significant advance.”

Funding from the National Cancer Institute supported this research.

Darrell E. Ward | EurekAlert!
Further information:
http://www.osu.edu

More articles from Life Sciences:

nachricht The birth of a new protein
20.10.2017 | University of Arizona

nachricht Building New Moss Factories
20.10.2017 | Albert-Ludwigs-Universität Freiburg im Breisgau

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Terahertz spectroscopy goes nano

20.10.2017 | Information Technology

Strange but true: Turning a material upside down can sometimes make it softer

20.10.2017 | Materials Sciences

NRL clarifies valley polarization for electronic and optoelectronic technologies

20.10.2017 | Interdisciplinary Research

VideoLinks
B2B-VideoLinks
More VideoLinks >>>